D. Western Therapeutics Institute Inc

Research D. Western Therapeutics Institute Inc (6DW) on Bullrun: market cap EUR 18.19M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6DW
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 18.19M
• Financial periodFY2025
• RevenueEUR 387.62M
• Revenue growth-17.8%
• Net income-EUR 632.09M
• Free cash flow-EUR 496.54M
• Gross margin90.0%

Valuation Snapshot

latest market cap is EUR 18.19M.

About D. Western Therapeutics Institute Inc

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining.

Frequently asked questions

What is D. Western Therapeutics Institute Inc's market cap?

D. Western Therapeutics Institute Inc's market capitalization is EUR 18.19M.

What does D. Western Therapeutics Institute Inc do?

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension;